BRAF and Ehlers-Danlos syndrome, musculocontractural type: We further confirmed the synergistic effect of NSAID and BRAFi combining diclofenac and dabrafenib (DBR), a B-raf inhibitor currently approved by FDA in combination with trametinib for BRAF-mutated ATCs (Fig. 7e, f for ATC and Supplementary Fig. S9H for PTC), further confirming the synergistic effect of NSAID and BRAFi.